MedTrace Logo

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

NCT01517945 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 252

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to test, customize, and personalize a mobile app-based intervention program in order to help rare and breast cancer survivors cope with fears of cancer recurrence.

Conditions

Interventions

BEHAVIORAL

AIM materials and assessments

Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10). Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial. Phase 3: * Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS * Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting * Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30) Phase 4: * Part 1 of Phase 4 (complete) - dev of iThrive app for RCS * Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely * Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90) For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session.

Sponsors & Collaborators

  • Brown University

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • Mclean Hospital

    collaborator OTHER

  • University of Southern California

    collaborator OTHER

  • The New School for Social Research

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Rebecca Saracino, PhD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01517945 on ClinicalTrials.gov